16.50 +0.54 (3.41%)
After hours: 4:38PM EDT
|Bid||15.92 x 800|
|Ask||17.43 x 800|
|Day's Range||15.86 - 16.96|
|52 Week Range||7.37 - 28.66|
|Beta (5Y Monthly)||1.40|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 30, 2020 - Aug 03, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||18.50|
Even though MEDNAX (MD) endures the COVID-19 impact on global economy, it holds prospects to revive its fortunes with the help of its initiatives and strong fundamentals.
Mark Roberts of Off Wall Street has been advising hedge funds for 30 years. Why he’s bearish on a software firm and a lubricants maker—and bullish on a gold stock.
MEDNAX's (MD) affiliate Jefferson Radiology collaborates with CDI for providing enhanced healthcare services to the Springfield community.
Jefferson Radiology, an affiliate of MEDNAX and Center for Diagnostic Imaging launch new collaborative partnership.
Moody's Investors Service ("Moody's") changed MEDNAX, Inc.'s ("MEDNAX") outlook to negative from stable. At the same time, Moody's affirmed the company's B1 Corporate Family Rating, the B1-PD Probability of Default Rating and the B1 ratings on its unsecured bonds due in 2023 and 2027. There is no change to the company's SGL-2 Speculative Grade Liquidity Rating.
Shares of Mednax (NYSE:MD) fell 10% after the company reported Q1 results.Quarterly Results Earnings per share fell 50.77% over the past year to $0.32, which missed the estimate of $0.56.Revenue of $845,918,000 lower by 0.62% year over year, which missed the estimate of $856,420,000.Looking Ahead Earnings guidance hasn't been issued by the company for now.Revenue guidance hasn't been issued by the company for now.How To Listen To The Conference Call Date: May 07, 2020View more earnings on MDWebcast URL: https://edge.media-server.com/mmc/p/pfdzzn4qRecent Stock Performance 52-week high: $29.97Company's 52-week low was at $7.37Price action over last quarter: down 35.97%Company Description Mednax Inc provides physician services, which include newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology, and other pediatric subspecialty care. The firm operates in six segments: neonatal and other pediatric subspecialties, anesthesia, maternal-fetal, pediatric cardiology, radiology, and other services. The neonatal segment contributes the largest proportion of the firm's revenue. Mednax generates virtually all of its revenue in the United States, with over half of its revenue from operations in five states: Texas, North Carolina, Georgia, Tennessee, and Florida. Contracted managed care payors contribute the majority of net collections.See more from Benzinga * Endo International: Q1 Earnings Insights * Newmark Group: Q1 Earnings Insights * Cooper Tire & Rubber: Q1 Earnings Insights(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Mednax (MD) delivered earnings and revenue surprises of -23.81% and 1.29%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
North American Partners in Anesthesia (NAPA) Acquires American Anesthesiology From MEDNAX, Inc.
Mednax (MD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Even though MEDNAX (MD) endures the COVID-19 impact on global economy, it holds high prospects to revive its fortunes by virtue of its solid fundamentals.
Moody's Investors Service, ("Moody's") today announced rating actions on 9 US healthcare services companies with businesses in physician staffing, travel nurse, locum tenens, radiology and diagnostic imaging to reflect the expected impact of business disruption caused by the coronavirus outbreak. As providers of various types of healthcare services, these companies are exposed to declining demand for their services due to factors including the postponement of elective procedures, lower emergency department volumes and closure of many non-emergent healthcare facilities. The US healthcare services sector has been one of the sectors affected by the shock given government and health association guidance to postpone all non-emergent healthcare services and take self-isolation measures.
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
GCP Applied Technologies said on Friday that its slate of board nominees will include two new independent directors and that it will expand the size of the board by one to 10 members. The Cambridge, Massachusetts-based chemical company is striking back at activist investor Starboard Value hours after the hedge fund announced on Thursday that it will push forward with its proxy fight and nominated eight directors. GCP named Armand Lauzon and John McPherson, executives with construction products expertise, as director candidates.
The rapid spread of the COVID-19 coronavirus is wreaking havoc across the equity market. The S&P; 500 lost nearly 13% from Feb. 19 to Feb. 28 - the fastest descent from all-time highs into correction territory in market history.Virtually all stocks have been affected by the growing scare. The worst stocks of the correction so far have all been pummeled by issues stemming from coronavirus - in particular, from the resulting rout in oil prices. Most of the best stocks (a handful of companies that managed to finish in the black) delivered gains based on the revenue opportunity that COVID-19 potentially represents, though a couple benefited from completely unrelated good news.To get a sense of what worked and what didn't, we screened the Russell 1000 Index, which includes the thousand largest companies on the U.S. equity market, for the best- and worst-performing stocks during the steep drawdown from Feb. 19 to Feb. 28. Both the Russell 1000 and S&P; 500 lost 12.8% over that period - predictably, biotechnology, travel and energy stocks were well represented among the stocks with the biggest moves.There were also a couple of pleasant surprises.Have a look at the five worst and five best stocks coming out of the market's epic February plunge. SEE ALSO: 11 Best Stocks to Ride Out the Coronavirus Outbreak